Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2011

View Archived Issues

First-in-class antimicrobial zempia is active against clinical bacterial isolates

Clinical study determines pharmacokinetics of oral formulation of antibiotic TP-434

Chemokine CCR8 receptor antagonist R-243 may prevent peritoneal adhesion

Impax Pharmaceuticals files IND for IPX-159 in restless legs syndrome

Boehringer Ingelheim patents new chemokine CCR1 receptor antagonists

Bayer Schering Pharma presents new MEK/ERK inhibitors

Merck & Co. presents novel kinase inhibitors

New modulators of muscarinic acetylcholine M1 receptor claimed

Novartis claims new sodium/glucose cotransporter 2 inhibitors

Sigma-Tau researchers disclose novel HD6 inhibitors

Johnson & Johnson recaps highlights of first quarter 2011

Pfizer outlines milestones for first quarter 2011 and future goals

Ustekinumab induces responses in patients with Crohn's disease

Phase II trial compares topical mechlorethamine formulations in mycosis fungoides

Sanford Project and DiaMedica complete animal study of DM-199

Merck & Co. completes tender offer to acquire Inspire Pharmaceuticals

Tourette Syndrome Association and Psyadon Pharmaceuticals collaborate on ecopipam

FDA approves Victrelis for chronic hepatitis C

Proteomika licenses HuCAL antibodies from AbD Serotec for use in Promonitor diagnostic kits

Nuvo Research expands pain portfolio with acquisition of ZARS Pharma

Chugai files to extend approval of CellCept to pediatric patients in Japan

Teva signs definitive agreement to acquire Taiyo Pharmaceutical

Alimera resubmits NDA for Iluvien in diabetic macular edema

Clavis Pharma licenses anticancer candidate CP-4033 to Translational Therapeutics

Roche begins phase Ib/II study of TB-403 in brain cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...